ARONORA, LLC

Basic Information

3500 SW BRIDLEMILE LN
PORTLAND, OR, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 804889348
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Therapeutic factor XI blockade for sepsis

    Amount: $2,957,729.00

    DESCRIPTION (provided by applicant): This SBIR Phase II grant will support the commercial development of an injectable biological product candidate, a unique proprietary recombinant humanized anti-fac ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Factor XI inhibitor for thrombosis

    Amount: $2,510,043.00

    DESCRIPTION (provided by applicant): Thrombotic cardiovascular diseases including venous thromboembolism (VTE), deep vein thrombosis (DVT), myocardial infarction, and ischemic stroke, remain leading c ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. Factor XI Inhibition for the Treatment of Ischemic Stroke

    Amount: $315,665.00

    DESCRIPTION (provided by applicant): One of the underlying causes of acute ischemic stroke (AIS) is the thrombotic-thromboembolic occlusion of cerebral blood vessels. Early use of tissue-type plasmino ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Factor XI inhibitor for thrombosis

    Amount: $309,528.00

    DESCRIPTION (provided by applicant): Thrombotic cardiovascular diseases including venous thromboembolism, myocardial infarction, and ischemic stroke, remain leading causes of death and disability in t ...

    SBIR Phase I 2011 Department of Health and Human Services
  5. Therapeutic thrombin analogs

    Amount: $1,771,244.00

    DESCRIPTION (provided by applicant): Stroke and heart attack are the leading causes of mortality and grave morbidity. The goal of this Fast-Track STTR grant application is to enable preclinical invest ...

    SBIR Phase II 2010 Department of Health and Human Services
  6. Therapeutic factor XI blockade for sepsis

    Amount: $297,486.00

    DESCRIPTION (provided by applicant): This Phase I SBIR grant will support the initial commercial development of a single dose injectable biological product candidate, recombinant humanized anti-factor ...

    SBIR Phase I 2010 Department of Health and Human Services
  7. Therapeutic thrombin analogs

    Amount: $457,672.00

    DESCRIPTION (provided by applicant): Stroke and heart attack are the leading causes of mortality and grave morbidity. The goal of this Fast-Track STTR grant application is to enable preclinical invest ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Development of a Sequencing Batch Biofilm Reactor for Treatment of Pesticide Rinsewater

    Amount: $75,000.00

    NON-TECHNICAL SUMMARY: Pesticide formulation and agricultural-chemical facilities generate a dilute troublesome pesticide rinsewater that is difficult to dispose of due to its low volume, highly varia ...

    SBIR Phase I 2003 Department of Agriculture

Agency Micro-sites

US Flag An Official Website of the United States Government